




Fungi are heterotrophic eukaryotes that are morphologically 
classified into their yeast and filamentous forms. Fungi are 
widely distributed in the environment, and while the majority 
of fungi are harmless to humans, some do cause various forms 
of disease, from superficial infestation and allergic diseases to 
life-threatening internal organ infections. 
The prevalence of fungal diseases has been increasing since 
the late 20th century due to an increase in the elderly popula- 
tion and an increase in patients with reduced immunity due to 
diabetes, AIDS, organ transplantation, and cancer. The host's 
immune response to fungi not only determines the clinical 
form of the fungal disease, but also greatly affects the host's 
susceptibility to the disease and the severity of the disease. 
The host's defense mechanisms against fungi are very com- 
plex, ranging from innate immune responses that cause non- 
specific immediate responses to pathogen infestations to 
highly specific acquired immune responses induced during 
infection. 
Recently, a great deal of new information has been dis- 
covered regarding innate immune responses and regulatory T 
cells involving antimicrobial peptides and pattern recognition 
receptors. There has been considerable research on the inter- 
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actions between different constituent cells and fungi, which 
have greatly increased the knowledge of human antifungal 
immune responses. The aim of this review is to provide an 
overview of the human immune response to fungi. 
FUNGAL RECOGNITION BY THE 
INNATE IMMUNE SYSTEM 
Innate immune mechanisms in humans respond to a variety 
of fungal pathogens in a fast and conserved manner. Con- 
stitutive mechanisms of innate immunity exist at the sites of 
interaction with the fungus and include the barrier function of 
the skin and the mucosal epithelial surfaces of the respiratory, 
gastrointestinal, and urogenital tract. Microbial antagonism 
and the complement system also provide defense mechanisms 
and opsonic recognition of fungi. For example, complement 
receptor 3 (CR3; heterodimer of CD11b and CD18) recognizes 
complement deposited on β-(1,6)-glucan on the fungal sur- 
face. In addition, the host cell may contain pattern recognition 
receptors (PRRs) such as toll-like receptors (TLRs), C-type 
lectin receptors (CLRs), and galectin family proteins that detect 
pathogen-associated molecular patterns (PAMPs) in fungi1. 
PRRs on phagocytic cells initiate downstream intracellular 
events that provoke activation of the immune system and 
elimination of fungi, with specific immune responses gener- 
ated according to the cell types involved. 
Those cell types include innate phagocytic cells such as 
neutrophils, monocytes, and macrophages, which are mostly 
involved in innate immunity to fungal species through phag- 
ocytosis or other direct killing mechanisms. On the other hand, 
dendritic cells (DCs) uptake fungi to induce DC maturation, so 
that mature DCs stimulate naïve T cells to become effector T 
helper cells. In this way, early recognition and inflammation 
against the fungus offer critical signals that drive adaptive 
immunity. 
Fungal cell walls show a combination of different compon- 
ents depending on the species, growth stage, and surrounding 
environment. Fungal cell walls play an important role in the 
recognition phase because they are the main source of PAMP, 
which is recognized by PRR in mammalian cells2. The three 
major cell wall components found in most medically important 
fungi are β-glucans, chitin, and mannans. During the course 
of fungal infection, a number of host PRRs are stimulated by 
the fungal PAMP in different combinations depending on the 
fungal species and the host cell type. Therefore, the final form 
of the immune response following the invasion of the fungus 
is influenced not only by the extent to which each receptor is 
stimulated, but also by the cooperation of activated receptors 
and the localization of cells. 
Detection of fungus-related molecular patterns, such as 
the cell wall component indicated above or intracellular con- 
stituents, depends on the expression of various kinds of PRRs 
in immune cells. From the discovery of TLRs as crucial mol- 
ecules in innate immunity, to the detection of dectin-1 as a β- 
glucan receptor, a wide variety of studies have led us to a 
strong understanding of the interactions between fungi and 
host immunity. PRRs can be classified into several families 
according to their function and molecular structure, such as 
C-type lectin receptors (CLRs), TLRs, and nucleotide-binding 
and oligomerization domain (NOD)-like receptors (NLRs). 
CLRs have central role for recognition of fungus by host 
immune system, and can be subclassified as dectin 1, dectin 
2, dectin 3, mincle, DC-specific ICAM3-grabbing non-integrin 
(DC-SIGN), macrophage mannose receptor 1, langerin, and 
mannose-binding lectin3. The main PRR is dectin 1, which 
detect β-glucans in fungal cell wall and induce the inflam- 
matory cytokines and chemokines3. This immune response is 
accomplished by two main cascades: the spleen tyrosine 
kinase (SYK)-caspase recruitment domain containing protein 
9 (CARD9) pathway and the RAF pathway. These two path- 
ways combine to promote or regulate the host immune 
responses to fungi, and ultimately activate nuclear factor-κB 
(NF-κB)4. Although it is not yet clear how CARD9 induces the 
activation of NF-κB following fungal infection, recent studies 
have shown that CARD9 serves as a link between dectin 2 
and NF-κB activation via IκBα kinase ubiquitination5, and also 
as a link between dectin 1 and ERK activation by turning on 
the RAS system6. The SYK-CARD9 pathway also stimulates 
the NLRP3 (NOD-, LRR and pyrin domain-containing inflam- 
masome), and the inflammasome promotes interleukin-1β 
and interleukin 18 by caspase 1. 
In a manner similar to dectin 1, dectin 2 recognizes high- 
mannose structures, mannose receptor, and DC-SIGN rec- 
ognize branched N-linked mannans to activate downstream 
immune responses. Dectin 2 binds mainly to hyphae with 
higher affinity than yeast, so that pairs with the Fc receptor γ- 
chain (FcRγ) to provoke the production of inflammatory cyto- 
kines. Mannose receptor and DC-SIGN bring the manno- 
sylated fungal antigen to DCs, which is linked to antigen 
processing and presentation to T cells7. Dectin 3 functions as 
a PRR by recognizing α-mannans8. Dectin 3 and dectin 2 
undergo heterodimerization, and this dimer can recognize α- 
mannans leading to higher sensitivity in recognition of Candida 
albicans than either dectin 2 or dectin 3 alone, and leading 
to strong activation of NF-κB-dependent immune responses 
against fungi9. This is supported by a previous report suggesting 
that dectin 3 deficiency results in lowered NF-κB activation 
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and cytokine production against Candida tropicalis in the 
gut10. 
Another major group of PRP is the TLRs. The main subtypes 
of TLRs, which are involved in the detection of fungal com- 
ponents, are TLR 2, TLR 4 and TLR 9. These subtypes detect 
the phospholipomannan, zymosan, fungal DNA and O-linked 
mannans11. There are several studies that have shown that 
mice lacking TLR signaling are highly susceptible to various 
fungal infections1, but the exact immunologic role of TLRs in 
fungal infection remains unclear. This ambiguity might be 
due to the diversity in fungal species, routes of infection, and 
pathogen-receptor coordination. Even though there is a debate 
about the relationship between TLR function and susceptibility 
to fungal infection, recent human studies have shown that 
TLR polymorphism is associated with the higher susceptibility 
to the specific fungal species12. For example, TLR 4 polymor- 
phism is associated with the higher susceptibility to candidial 
sepsis13, and TLR 9 polymorphism is associated with allergic 
bronchopulmonary aspergillosis (ABPA)14. Similar to CLRs, TLRs 
also promote the antigen-presentation of fungal component 
to DCs, which promote T cell responses to fungi. With regard 
to immunological cascades, the stimulation of TLRs by fungal 
antigens induces downstream signaling of the protease- 
activated receptors (PARs)15. PARs, which are G protein- 
coupled receptors, are activated by fungal proteases as well 
as host proteases that are activated by fungal-host immune 
reaction. Once TLRs detect the fungal antigens, PARs are 
activated and are able to detect various virulence factors 
associated with host tissue injury. There are two types of 
PARs; PAR 1 mediates pro-inflammatory responses, whereas 
PAR 2 mediates anti-inflammatory responses. So, TLR and PAR 
signaling cascades affect each other to regulate immune 
responses to the fungi15. 
Although little is known about the cytoplasmic receptors 
that respond to fungi, NOD-like receptors (NLRs) are known 
to recognize fungi and, if activated, promote the secretion 
of IL-1β and IL-18 via production of the inflammasome16. For 
example, in mice that lack IL-1 receptor type I (IL-1RI) signaling, 
different susceptibility patterns by aberrant activation of IL-18 
or caspase 1 have been identified11. However, mice lacking 
NLRP3 show increased sensitivity to Candida infections17. 
Defective activation of NLRP3 is known to be linked to in- 
creased C. albicans colonization and the deterioration of 
Crohn's disease18. These observations demonstrate how com- 
mensal fungi such as C. albicans become pathogenic under 
certain circumstances. 
Mammalian PRRs recognize not only PAMPs, but also by- 
products of cells that have been destroyed by external patho- 
gens, such as nucleic acids, which are called damage-associated 
molecular patterns (DAMPs)19. Although specific signaling 
pathways that regulate immune responses induced by PAMPs 
and DAMPs have been identified, unexpectedly, the fact that 
molecular pathways recognizing PAMPs and DAMPs converge 
to common specific pathways has been also identified. This 
raises the questions of whether the host immune system 
distinguishes between these two types of molecular patterns, 
and how they do so. It is not clear to what extent these two 
different molecular patterns, PAMPs and DAMPs, contribute 
to the mechanisms of inflammation, immune homeostasis, 
and repair that occur during the course of fungal infection. 
However, a mechanism has recently been proposed to explain 
how host immunity can distinguish immune responses from 
PAMPs and DAMPs. A key molecule is alarmin S100 B, which 
distinguishes host-specific immune response from PAMPs 
from those from DAMPs by spatiotemporally integrating the 
signal from TLRs with the receptors for the advanced glycation 
end-product (RAGE)20. When a nucleic acid, a type of DAMP, 
binds to a TLR2 ligand derived from a fungus, S100B inhibits 
the inflammation induced by TLRs. Thereafter, intracellular 
TLR3 and TLR9 are activated, leading to downregulation of 
the immune response. Thus, the interaction of RAGE with 
TLRs represents a regulatory circuit in the response to fungal 
infection; the endogenous danger signal protects the host 
from excessive inflammation due to fungal infection, and 
terminates the inflammation by DAMPs sensing mechanism. 
This suggests the interesting possibility that the host may have 
developed PAMPs to modulate excessive immune responses 
by DAMPs. 
DENDRITIC CELLS 
Dendritic cells (DCs) are specialized antigen presenting cells 
that take up antigens, integrate local inflammation signals, 
and migrate to lymph nodes, which drain the affected area, 
effectively leading to adaptive fungal immune responses. For 
example, analysis of DCs activated by fungi through whole- 
genome transcriptional analysis suggests that there are specific 
transcription programs that result from fungal infection21. 
The fact that this group of specific DCs has a variety of pro- 
grams, and the fact that the characteristic intracellular sig- 
naling system is paired with different PRRs22, suggests that 
there is great plasticity of the DC system and the T cell immune 
response23. The immune response of DCs to different adaptive 
fungi is also affected by cooperation and specialization be- 
tween DC subgroups. Inflammatory DCs induce Th17 and Th2 
cell responses via the TLR adaptor MYD88, while tolerogenic 
DCs promote differentiation into regulatory T (Treg) and Th1 
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cells via TLR Adaptor Molecule 1 (TICAM). In addition, signal 
transducer and activator of transcription 3 (STAT3) affects the 
balance between canonical and non-canonical activation of 
NF-kB, by inducing expressing an enzyme called indoleamine 
2,3-dioxygenase (IDO), which plays a key role in the plasticity 
of DCs and in the formation of functional specialization. 
Various signaling systems of functionally independent DCs 
ultimately control the balance between CD4+ T cells and Treg 
cells and determine whether fungi cause infection or maintain 
commensalism. 
DCs direct a specific T cell immune response through a 
variety of factors, including the nature of the fungal pathogen, 
the site of infection, and the susceptibility of the host. For 
example, the DC subset present in the skin (skin-resident T 
cell) triggers a characteristic T-helper immune response. In 
previous studies of C. albicans infection models, langerhans 
cells are necessary and sufficient to induce differentiation into 
Th17 cells, but dermal DCs expressing Langerin are required 
to induce differentiation into Th1 cells and cytotoxic T cells, 
which has been shown to interfere with the Th17 response24. 
Morphological characteristics of fungi also affect the differ- 
entiation of T helper cells. The yeast forms of C. albicans can 
induce a Th17 response by langerhans cells, which results in 
IL-6 production through interacting with dectin-125. In contrast, 
the filamentous form has a morphological characteristic that 
prevents interaction with dectin-1, causing a Th1 response. In 
addition, IL-23 production is increased from dermal DCs by 
stimulation of nociceptive sensory nerves to protect against 
skin infections of C. albicans, which promotes IL-17 production 
by dermal γδ T cells and subsequent antifungal action of 
neutrophils26. 
LYMPHOCYTES 
There are three main T cell subtypes involved in fungal 
infection of humans: Th1, Th2, and Th17 cells. Th1 cells are 
highly associated with protective immunity to fungal species 
27-29. As with any T cell response, differentiation into Th1 
cells is determined by the DC's response to the combination 
of TLR and CLR signals induced by the fungal infection. By 
indirectly assisting the production of opsonizing antibodies 
and the production of IFNγ, a representative cytokine, Th1 
cells play a fundamental and essential role in the activation 
of phagocytes in infected areas. Thus, the inability of T cells to 
properly transmit activation signals to phagocytes in infected 
areas can lead to uncontrollable infections or prevent proper 
treatment efficacy by antifungal agents. The adaptive immune 
response to commensal fungi, called delayed-type hypersen- 
sitivity, acts as a defense against fungi in the host with normal 
immune function, and there is a relatively favorable prognosis 
when this reaction occurs. For example, the antibodies to the 
cryptococcal antigen is found in immunocompetent host in 
high prevalence, which indicates the Th1 immune response 
occurs after the initial infection, thereby causing the growth 
of the fungus and acquired immunity against the fungus28. 
Th2 cells are differentiated from naive T cells in their pro- 
duction of IL-4 and IL-13, which buffer the fungal defense 
effect by the Th1 cell immune response by secreting IL-5 and 
lead to the activation of macrophages in the other direction 
than Th1 cell response. As opposed to Th1 cells, immune 
responses by Th2 cells are involved in fungal infection, fungal 
allergic reactions, and recurrence of fungal infections30. In 
atopic dermatitis patients and newborns, delayed hypersen- 
sitivity reaction by Th1 cell responses is suppressed, which is 
associated with increased levels of IgE, IgA, and IgG against 
fungi. In addition, ABPA is known to occur when Th2 cell 
reactivity is increased in cystic fibrosis patients31. However, 
some studies have shown that humoral immune responses 
by Th2 cells play a protective role against fungi, as do Th1 cells, 
and together with these responses resolve the excess fungal 
levels inside macrophages and affects gene expression in 
fungi32,33. 
Th17 cells play a major immune response in the mucosal 
fungal infection. IL-17, the most important cytokine in mucosal 
fungal infections, is produced by Th17 cells and γδT cells to 
protect mucosal and skin from Candida infections34,35. Th17 
cells are also activated by the signaling systems of SYK-CARD9, 
MYD88, and mannose receptors, which promote the activa- 
tion of neutrophils and definsin production in mucosa. This 
promotes Th1 cell immune responses and suppresses Th2 
cell immune responses against fungal infections in various 
parts of the body. Indeed, previous experimental studies have 
shown that in mucosal candidiasis infection36, Th17 cells 
assist the response of Th1 cells, and that not only Th1 but also 
Th17 cell responses are defective in patients with chronic 
mucocutaneous candidiasis37. However, there are still many 
conflicting opinions on whether IL-17 and IL-17 receptor 
interactions are essential for the activation of Th17 cells. This 
indicates that the extent of infection, the site of infection, 
and the microenviroment of the fungal infection site deter- 
mine whether the Th17 cell immune response is activated38. 
On the other hand, in Candida infection, the Th17 immune 
response is inhibited by Candida species39, and if the Th17 
immune response is not inhibited properly, complete reso- 
lution of the fungal infection is not achieved and chronic 
inflammation occurs40. A mechanism that connects inflam- 
mation and chronic fungal disease could be excessive Th17 
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immune response, which impedes proper fungal defense 
and ensures that fungi remain at the site of infection. Taken 
together, the Th17 immune response is thought to be asso- 
ciated with chronic fungal disease, in which continued fungal 
secretion of antigens disrupts the host's immune system41. 
In addition to Th1, Th2 and Th17 cells, Treg cells play a major 
role in the defense against fungal infections. In the course of 
fungal infection, the ultimate goal of the immune response 
is to completely eliminate pathogenic fungi while minimizing 
damage to the host tissue by the immune response. Many 
clinical studies of fungal infection have shown an inverse 
relationship between IFNγ and IL-10 production. High levels 
of IL-10 in patients with chronic Candida infection inhibit IFNγ 
production, and high levels of IL-10 have been observed in 
severe fungal infections, such as aspergillosis in patients with 
neutropenia, and in various endemic mycoses. Those studies 
indicate that there is a link between high levels of IL-10 and 
susceptibility to fungal infections42. Despite these facts, IL-10 
production is thought to be a consequence, rather than a 
cause, of infection. This implies that IL-10 is the product of a 
homeostatic immune response to control the inflammatory 
response in cases of chronic fungal infections that cause poorly 
controlled, persistent inflammation42. The anti-inflammatory 
activity of Treg cells in fungal infections has been demon- 
strated in human and mouse experiments. In studies of fungal 
infections, inflammatory responses and immune tolerance are 
shown to be regulated with close cooperation between dif- 
ferent subgroups of Treg cells. However, the immune response 
of Treg cells has the potential to limit the effects of protective 
immune responses, not only by reducing host damage, but 
also by leading to chronic fungal infection and eventually to 
an immunosuppressed state43. Thus, by regulating the mag- 
nitude and quality of innate and adaptive immune responses, 
Treg cells induce a variety of immune responses, ranging 
from apparent immunosuppressive conditions to protective 
tolerance, which ensures the survival of the host without 
completely eliminating pathogenic fungi. This indicates that 
the host immune response and fungi interact with each 
other to determine whether the fungi are present as normal 
biota or as a pathogen. 
In addition to the above-mentioned types of T cells, attention 
has recently focused on the role of tissue-resident memory T 
cells (TRM), which is another important subgroup of T cells 
discovered in the early 2000s. In a physiological environment, 
TRM cells live in epidermal barrier tissue and are involved in 
interactions between the external environment and the host. 
TRM cells induce a rapid immune response against antigens 
that penetrate the epidermal barrier independently of the 
recruitment of T cells in the blood44,45, and activate the rapid 
protective immune system as one of the representative fea- 
tures of adaptive immune system45. This is because TRM cells 
form a specific population against certain pathogens which 
is previously encountered in the barrier tissue, and thus have 
different T cell receptor repertoire depending on the type of 
epidermal barrier tissue46. 
In particular, CD4+ TRM cells in papillary dermis contain popu- 
lations specific for viruses, fungi, and protozoa. It is known 
to include a population that is specific to C. albicans, which 
has similar immunophenotype as Th17 cells, as well as HSV 
and Leishmania spp47-49. In addition, CD4+ TRM cells, like CD8
+ 
TRM cells, face the challenge of pathogens, promote rapid 
activation of the immune system, and serve to quickly remove 
pathogens from the skin49. In support of this fact, local skin 
infections caused by external pathogens resulted in a sharp 
increase in the number of CD8+ TRM cells, as well as CD4
+ TRM 
cells, in infected areas, whereas a decrease in the number of 
TRM cells resulted in unaffected sites, thus providing global 
defense49. 
For example, a recent study using a mice model showed 
that long-lived populations of Th17 CD4+ TRM cells increase 
after cutaneous C. albicans infection, which are responsible for 
the defense of local infection. On the other hand, migratory 
T cells do not reside in the skin, and do not share the Th17 
immunophenotype, suggesting that there is a clear role-sharing 
between TRM and migratory T cells
49. 
Natural killer (NK) cells represent the prototype of lympho- 
cytes in innate immunity. NK cells, together with Th1 cells, are 
classified as group 1 T cells, and their commonality is that they 
secrete IFNγ as a major cytokine. NK cells kill various patho- 
genic fungi directly by secreting perforin. For example, the 
action of perforin on C. neoformans requires PI3K-dependent 
ERK1/2 signaling in NK cells50. NK cells secrete GM-SCF and 
IFNγ, which are involved in promotion of neutrophil action51. 
Recently, studies have been conducted on the mechanism by 
which NK cells recognize fungi. NKp30 receptors are involved 
in the recognition of Candida and Cryptococcus and kill them 
by releasing perforin52. In addition, NKp46 was involved in the 
recognition and killing of Candida glabrata53, and CD56 was 
found to be involved in NK cell activation and inflammatory 
cytokine secretion by Aspergillus54. Recently, studies are un- 
derway to attempt to prophylaxis or treat invasive fungal 
infections using fungal recognition mechanism of NK cells. 
THERAPEUTIC IMPLICATION OF HOST- 
FUNGAL INTERACTION 
Fungi are organisms composed of eukaryotes, unlike bac- 
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teria and viruses, so they are very similar in structure and 
function to mammalian cells. For this reason, the development 
of antifungal drugs is complicated and the cost is high enough 
to hamper the development antifungal therapeutics. However, 
with an increasing understanding of fungal and host inter- 
actions, immunological therapeutic approaches are currently 
under investigation. The first attempted treatment focused 
on recombinant cytokines. For instance, a method has been 
employed, with varying degrees of success. to synthesize GM- 
CSF or G-CSF and administer it into the body to increase the 
population of myeloid lymphocytes and to promote antifungal 
action of neutrophils. Treatment with IFN-γ was developed 
to promote the phagocytic function of macrophages and to 
restore a defective Th1 cell immune response, and these have 
been introduced as an adjuvant therapy to chronic granu- 
lomatous disease and cryptococcal meningitis55. 
Cellular immunotherapy is recognized as a new approach 
to treating fungal infections. With injection of anti-Aspergillus 
T cells, the survival rate of hematopoietic stem cell transplant 
patients is improved56. In addition, genetically engineered T 
cells expressing antigen receptors with specificities similar to 
those for dectin-1 are known to be effective in the treatment 
of aspergillosis in animal models57. Innate immune cell therapy 
is also in the spotlight as an effective alternative therapy. In 
animal models, dendritic cells treated with Aspergillus conidia 
or inoculated with RNA of conidia have been shown to 
activate antigen-specific Th1 cell immune responses. Most 
of the above-described treatments using immune cells are in 
the preclinical phase. However, Aspergillus-specific T cells were 
used to treat hematopoietic stem cell transplantation patients, 
which resulted in higher T cell responses and elevated levels 
of IFNγ and IL-1056. 
Due to the difficulty of developing antifungal agents, there 
is also a effort underway to prevent invasive fungal infection 
by inoculating immunosuppressed patients with vaccines 
against fungi. However, immunosuppressed patients may fail 
to produce an appropriate immune response to the vaccine 
due to lowered function of the immune system, and there is 
a question about the efficacy and safety and this approach. 
To overcome this problem, vaccines are being developed that 
engage elements of the immune system that are relatively 
intact55. Yet, there is no fungal vaccine available in the clinical 
field. However, recent studies using fungal cell wall molecules 
have been published58. For example, a vaccine consisting of 
laminarin and diphtheria toxoid, centered on β-glucan, led to 
acquired immunity against Candida or Aspergillus in animal 
experiments59. In another animal experiment, it was shown 
that a subcutaneous vaccine composed of glucan particles 
extracted from Cryptococcus induce a robust Th1 and Th17 
immune response to prevent cryptococcosis60. Most recently, a 
phase I study of a vaccine composed of recombinant Candida- 
derived proteins showed acquired immunity against Candida 
and is the most anticipated fungal vaccine for humans61,62. 
CONCLUSIONS AND FUTURE 
PERSPECTIVES 
As the number of immunosuppressed patients increases, 
not only the mucocutaneous fungal infection, but also the 
incidence and prevalence of invasive fungal infections are 
increasing. However, the pace of development of therapeutic 
agents for fungal infections is not keeping up with the in- 
creasing prevalence. Over the last few decades, in-depth re- 
search on innate and acquired immune responses to fungi has 
been undertaken, and attempts have been made to establish 
various treatment techniques using the immune response, 
as described above. 
The enhancement of antifungal effects through the host 
natural immune response is emerging as a treatment option 
for future fungal infections. There are questions about the 
safety and effectiveness of the drugs under investigation, but 
clinical studies are underway on immunosuppressive patients. 
An alternative approach is to modulate the key regulators of 
the immune response. For example, immune responses to 
fungi, whether innate or acquired, are caused by major fungal 
recognition systems, such as TLRs, MYD88, and microRNAs. 
Modulations to these molecules might be able to increase 
antifungal resistance. 
In summary, the above-mentioned immune responses and 
related studies provide an optimistic prospect for future anti- 
fungal immunotherapy. Recent research on fungal immunity 
by fungal immunologists has enhanced the understanding 
of various aspects of the regulation of antifungal immune 
responses from the organism level to the molecular level, along 
with innate immune recognition, inflammatory responses, 
and adaptive immunity. 
The results of ongoing studies will reveal more diverse 
fungal receptors and immune responses in the future, and 
animal model experiments and human genetic studies will 
also be integrated into each other, broadening our under- 
standing of fungal infection. Studies on how fungal compos- 
ition, diversity, and metabolism affect immune homeostasis 
and inflammatory diseases are ongoing, and these studies will 
give us deeper understanding not only about fungal infections, 
but also inflammatory diseases that involve immune responses 
against fungi, including atopic dermatitis, Crohn's disease, 
and ulcerative colitis. 
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